Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000058.xml
Download PDF
Planta Med 2008; 74(11): 1323-1337
DOI: 10.1055/s-2008-1081314
DOI: 10.1055/s-2008-1081314
Pharmacology
Review© Georg Thieme Verlag KG Stuttgart · New York
Plant-Derived Leading Compounds for Chemotherapy of Human Immunodefiency Virus (HIV) Infection – An Update (1998 – 2007)
Further Information
Publication History
Received: April 5, 2008
Revised: June 2, 2008
Accepted: June 6, 2008
Publication Date:
31 July 2008 (online)
Abstract
The high number of citations of the previous review on anti-HIV compounds from plants published in 1998 in Planta Medica indicates the importance of natural products research in the battle against HIV. Therefore, we have decided to write an update of our previous review paper, this time covering the time span 1998 – 2007. The following antiviral chemical classes are discussed in detail: alkaloids, carbohydrates, coumarins, flavonoids, lignans, phenolics, proteins, quinones/xanthones, tannins and terpenes. If available, chemical structures, antiviral activity and selectivity, mechanism of action, and structure-activity relationship are presented.
Key words
HIV - antiviral activity - plant-derived products - natural products - anti-HIV properties - anti-AIDS products
References
- 1 Vlietinck A J, De Bruyne T, Apers S, Pieters L. Plant-derived leading compounds for chemotherapy of human immunodefiency virus (HIV) infection. Planta Med. 1998; 64 97-109
- 2 Matthee G, Wright A D, König G. HIV reverse transcriptase inhibitors of natural origin. Planta Med. 1999; 65 493-506
- 3 Cos P, Vanden Berghe D, De Bruyne T, Vlietinck A J. Plant substances as antiviral agents: An update (1997 – 2001). Curr Org Chem. 2003; 7 1163-80
- 4 Cos P, Maes L, Vanden Berghe D, Hermans N, Pieters L, Vlietinck A. Plant substances as anti-HIV agents selected according to their putative mechanism of action. J Nat Prod. 2004; 67 284-93
- 5 De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov. 2007; 6 1001-18
- 6 Pomerantz R J, Horn D L. Twenty years of therapy for HIV-1 infection. Nat Med. 2003; 9 867-73
- 7 Flexner C. HIV drug development: the next 25 years. Nat Rev Drug Disov. 2007; 6 959-66
- 8 Cos P, Vlietinck A J, Vanden Berghe D, Maes L. Anti-infective potential of natural products: how to develop a stronger in vitro ‘proof-of-concept’. J Ethnopharmacol. 2006; 106 290-302
- 9 White E L, Chao W R, Ross L J, Borhani D W, Hobbs P D, Upender V. et al . Michellamine alkaloids inhibit protein kinase C. Arch Biochem Biophys. 1999; 365 25-30
- 10 Hallock Y F, Manfredi K, Dai J, Cardellina JH I I, Gulakowski R J, McMahon J B. et al . Michellamines D – F, new HIV-inhibitory dimeric naphthylisoquinoline alkaloids, and korupensamine E, a new antimalarial monomer, from Ancistrocladus korupensis. J Nat Prod. 1997; 60 677-83
- 11 Bringmann G, Holenz J, Weirich R, Rübenacker M, Funke C, Boyd M R. et al . First synthesis of the antimalarial naphthylisoquinoline alkaloid dioncophylline C, and its unnatural anti-HIV dimer, jozimine C. Tetrahedron. 1998; 54 497-512
- 12 Bringmann G, Wenzel M, Ross Kelly T, Boyd M R, Gulakowski R J, Kaminsky R. Octadehydromichellamine, a structural analog of the anti-HIV michellamines without centrochirality. Tetrahedron. 1999; 55 1731-40
- 13 Karpas A, Fleet G WJ, Dwek R A, Petursson S, Namgoong S K, Ramsden N G. et al . Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci USA. 1988; 85 9229-33
- 14
Watson A A, Fleet G WJ, Asano N, Molyneux R J, Nash R J.
Polyhydroxylated alkaloids – natural occurrence and therapeutic applications.
Phytochemistry.
2001;
56
265-95
MissingFormLabel
- 15 Taylor D L, Nash R, Fellows L E, Kang M S, Tyms A S. Naturally occurring pyrrolizidines: Inhibition of α-glucosidase 1 and anti-HIV activity of one stereoisomer. Antiviral Chem Chemother. 1992; 3 273-7
- 16 Asano N, Nishida M, Kato A, Kizu H, Matsui K, Shimada Y. et al . Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases. J Med Chem. 1998; 41 2565-71
- 17 Matsuno T, Orita K, Edashige K, Kobuchi H, Sato E F, Inouye B. et al . Inhibition of active oxygen generation in guinea-pig neutrophils by biscoclaurine alkaloids. Biochem Pharmacol. 1990; 39 1255-9
- 18 Kondo Y, Imai Y, Hojo H, Hashimoto Y, Nozoe S. Selective inhibition of T-cell dependent immune responses by bisbenzylisoquinoline alkaloids in vivo. Int J Immunopharmacol. 1992; 14 1181-6
- 19 Furusawa S, Wu J. The effects of biscoclaurine alkaloid cepharantine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sci. 2007; 80 1073-9
- 20 Legrand-Poels S, Vaira D, Pincemail J, Van de Vorst A, Piette J. Activation of human immunodeficiency virus type 1 by oxidative stress. AIDS Res Hum Retroviruses. 1990; 6 1389-97
- 21 Okamoto M, Ono M, Baba M. Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. AIDS Res Hum Retroviruses. 1998; 14 1239-45
- 22 Longanga Otshudi A, Apers S, Pieters L, Claeys M, Pannecouque C, De Clercq E. et al . Biologically active bisbenzylisoquinoline alkaloids from the root bark of Epinetrum villosum. J Ethopharmacol. 2005; 102 89-94
- 23 Duan H, Takaishi Y, Imakura Y, Jia Y, Li D, Cosentino M. et al . Sesquiterpene alkaloids from Tripterygium hypoglaucum and Tripterygium wilfordii: A new class of potent anti-HIV agents. J Nat Prod. 2000; 63 357-61
- 24 Ishida J, Wang H K, Oyama M, Cosentino M L, Hu C Q, Lee K H. Anti-AIDS agents. 46. Anti-HIV activity of harman, an anti-HIV principle from Symplocos setchuensis, and its derivatives. J Nat Prod. 2001; 64 958-60
- 25 Meragelman K M, McKee T C, Boyd M R. Siamenol, a new carbazole alkaloid from Murraya siamensis. J Nat Prod. 2000; 63 427-8
- 26 Kongkathip B, Kongkathip N, Sunthitikawinsakul A, Napaswat C, Yoosook C. Anti-HIV-1 constituents from Clausena excavata: Part II. Carbazoles and a pyranocoumarin. Phytother Res. 2005; 19 728-31
- 27 Xu Z, Chang F R, Wang H K, Kashiwada Y, McPhail A T, Bastow K F. et al . Anti-HIV agents 45 and antitumour agents 205. Two new sesquiterpenes, leitneridanins A and B, and the cytotoxic and anti-HIV principles from Leitneria floridana. J Nat Prod. 2000; 63 1712-5
- 28 Hsieh P W, Chang F R, Lee K H, Hwang T L, Chang S M, Wu Y C. A new anti-HIV alkaloid, drymaritin, and a new C-glycoside flavonoid, diandroflavone, from Drymaria diandra. J Nat Prod. 2004; 67 1175-7
- 29 Silva E M, Cirne-Santos C C, Frugulhetti I CPP, Galvao-Castro B, Saraiva E MB, Kuehne M E. et al . Anti-HIV activity of the Iboga alkaloid congener 18-methoxycoronaridine. Planta Med. 2004; 70 808-12
- 30 Leven M, Vanden Berghe D A, Vlietinck A J. Plant antiviral agents IV. Influence of lycorine on growth pattern of three animal viruses. Planta Med. 1983; 49 109-14
- 31 Szlavik L, Gyuris A, Minarovits J, Forgo P, Molnar J, Hohmann J. Alkaloids from Leucojum vernum and antirettroviral activity of Amaryllidaceae alkaloids. Planta Med. 2004; 70 871-3
- 32 Wu P L, Lin F W, Wu T S, Kuoh C S, Lee K H, Lee S J. Cytotoxic and anti-HIV principles from the rhizomes of Begonia nantoensis. Chem Pharm Bull. 2004; 52 345-9
- 33 Mann D A, Frankel A D. Endocytosis and targeting of exogenous HIV-1 tat protein. EMBO J. 1991; 10 1733-9
- 34 Rusnati M, Urbinati C, Caputo A, Possati L, Lortat-Jacob H, Giacca M. et al . Pentosan sulfate as an inhibitor of extracellular HIV-1 tat. J Biol Chem. 2001; 25 22 420-5
- 35 Rusnati M, Coltrini D, Oreste P, Zoppetti G, Albini A, Noonan D. et al . Interaction of HIV-1 tat protein with heparin. J Biol Chem. 1997; 17 11 313-20
- 36 Watson K, Gooderham N J, Davies D S, Edwards R J. Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides. Biochem Pharmacol. 1999; 57 775-83
- 37 Lüscher-Mattli M. Polyanions – a lost chance in the fight against HIV and other virus diseases?. Antiviral Chem Chemother. 2000; 11 249-59
- 38 Witvrouw M, De Clercq E. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol. 1997; 29 497-511
- 39 Esté J A, Schols D, De Vreese K, Van Laethem K, Vandamme A M, Desmyter J. et al . Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol Pharmacol. 1997; 52 98-104
- 40 Abrams D I, Kuno S, Wong R, Jeffords K, Nash M, Molaghan J B. et al . Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med. 1989; 110 183-8
- 41 Flexner C, Barditch-Crovo P A, Kornhauser D M, Farzadegan H, Nerhood L J, Chaisson R E. et al . Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother. 1991; 35 2544-50
- 42 Hiebert L M, Wice S M, Jaques L B, Williams K E, Conly J M. Orally administered dextran sulfate is absorbed in HIV-positive individuals. J Lab Clin Med. 1999; 133 161-70
- 43 Shaunak S, Thornton M, John S, Teo I, Peers E, Mason P. et al . Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulfate in patients with AIDS. AIDS. 1998; 12 399-409
- 44 De Clercq E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev. 2000; 20 323-49
- 45 Hoshino T, Hayashi T, Hayashi K, Hamada J, Lee J B, Sankawa U. An antivirally active sulfated polysaccharide from Sargassum horneri (Turner) C. Agardh. Biol Pharm Bull. 1998; 21 730-4
- 46 Lee J B, Hayashi K, Hayashi T, Sankawa U, Maeda M. Antiviral activities against HSV-1, HCMV, and HIV-1 of rhamnan sulfate from Monostroma latissimum. Planta Med. 1999; 65 439-41.
- 47 Haslin C, Lahaye M, Pellegrini M, Chermann J C. In vitro anti-HIV activity of sulfated cell-wall polysaccharides from gametic, carposporic and tetrasporic stages of the Mediterranean red alga Asparagopsis armata. Planta Med. 2001; 67 301-5
- 48 Rechter S, König T, Auerochs S, Thulke S, Walter H, Dörnenburh H. et al . Antiviral activity of Arthrospira-derived spirulan-like substances. Antiviral Res. 2006; 72 197-206
- 49 Kashman Y, Gustafson K R, Fuller R W, Cardellina J H, McMahon J B, Currens M J. et al . The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem. 1992; 35 2735-43
- 50 Ishikawa T. Anti-HIV-1 active Calophyllum coumarins: distribution, chemistry and activity. Heterocycles. 2000; 53 453-74
- 51 Zembower D E, Liao S, Flavin M T, Xu Z Q, Stup T L, Buckheit R W. et al . Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C)1. J Med Chem. 1997; 40 1005-17
- 52 Dharmaratne H RW, Tan G T, Marasinghe G PK, Pezzuto J M. Inhibition of HIV-1 reverse transcriptase and HIV-1 replication by Calophyllum coumarins and xanthones. Planta Med. 2002; 68 86-7
- 53 Yu D, Suzuki M, Xie L, Morris-Natschke S L, Lee K H. Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med Res Rev. 2003; 23 322-45
- 54 Dharmaratne H RW, Wanigasekera W MAP, Mata-Greenwood E, Pezzuto J M. Inhibition of human immunodeficiency virus type 1 reverse transcriptase activity by cordatolides isolated from Calophyllum cordato-oblongum. Planta Med. 1998; 64 460-1
- 55 Quan Y, Motakis D, Buckheit R, Xu Z Q, Flavin M T, Parniak M A. et al . Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase. Antiviral Ther. 1999; 4 203-9
- 56 Buckheit R W, White E L, Fliakis-Boltz V, Russell J, Stup T L, Kinjerski T L. et al . Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother. 1999; 43 1827-34
- 57 Buckheit R W, Russell J, Xu Z Q, Flavin M. Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HOV-1 replication. Antiviral Chem Chemother. 2000; 11 321-7
- 58 Xu Z Q, Hollingshead M G, Borgel S, Elder C, Khilevich A, Flavin M T. In vivo activity of (+)-calanolide A in the hollow fiber mouse model. Bioorg Med Chem Lett. 1999; 9 133-8
- 59 Xu Z Q, Norris K J, Weinberg D S, Kardatzke J, Wertz P, Frank P. et al . Quantification of (+)-calanolide A, a novel and naturally occurring anti-HIV agent, by high-performance liquid chromatography in plasma from rat, dog and human. J Chromatogr B. 2000; 742 267-75
- 60 Newman R A, Chen W, Madden T L. Pharmaceutical properties of related calanolide compounds with activity against human immunodeficiency virus. J Pharm Sci. 1998; 87 1077-80
- 61 Sorbera L A, Castaner R M. Calanolide A. Drugs Fut. 2001; 26 285-6
- 62 Creagh T, Ruckle J L, Tolbert D T, Giltner J, Eiznhamer D A, Dutta B. et al . Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother. 2001; 45 1379-86
- 63 Kostova I, Raleva S, Genova P, Argirova R. Structure-activity relationships of synthetic coumarins as HIV-1 inhibitors. Bioorg Chem Appl. 2006; 68 274 1-9
- 64 Chen Y, Zhang Q, Zhang B, Xia P, Xia Y, Yang Z Y. et al . Anti-AIDS agents. Part 56: Synthesis and anti-HIV activity of 7-thia-di-O-(–)-camphanoyl-(+)-cis-khellolactone (7-thia-DCK) analogs. Bioorg Med Chem. 2004; 12 6383-7
- 65 Marquez N, Sancho R, Bedoya L M, Alcami J, Lopez-Perez J L, San Feliciano A. et al . Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kB pathway. Antiviral Res. 2005; 66 137-45
- 66 Kitamura K, Honda M, Yoshizaki H, Yamamoto S, Nakane H, Fukushima M. et al . Baicalin, an inhibitor of HIV-1 production in vitro. Antiviral Res. 1998; 37 131-40
- 67 Xu H X, Wan M, Dong H, But P PH, Foo L Y. Inhibitory activity of flavonoids and tannins against HIV-1 protease. Biol Pharm Bull. 2000; 23 1072-6
- 68 Kim H J, Woo E R, Shin C G, Park H. A new flavonol glycoside gallate ester from Acer okamotoanum and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase. J Nat Prod. 1998; 61 145-8
- 69 Critchfield J W, Coligan J E, Folks T M, Butera S T. Casein kinase II is a selective target of HIV-1 transcriptional inhibitors. Proc Natl Acad Sci USA. 1997; 94 6110-5
- 70 Haneda E, Furuya T, Asai S, Morikawa Y, Ohtsuki K. Biochemical characterization of casein kinase II as a protein kinase responsible for stimulation of HIV-1 protease in vitro. Biochem Biophys Res Commun. 2000; 275 434-9
- 71 Harada S, Haneda E, Maekawa T, Morikawa Y, Funayama S, Nagata N. et al . Casein kinase II (CK-II)-mediated stimulation of HIV-1 reverse transcriptase activity and characterization of selective inhibitors in vitro. Biol Pharm Bull. 1999; 22 1122-6
- 72 Wu J H, Wang X H, Yi Y H, Lee K H. Anti-AIDS agents 54. A potent anti-HIV chalcone and flavonoids from genus Desmos. Bioorg Med Chem Lett. 2003; 13 1813-5
- 73 Nakagawa-Goto K, Lee K H. Anti-AIDS agents 68. The first total synthesis of a unique potent anti-HIV chalcone from genus Desmos. Tetrahedron Lett. 2006; 47 8263-6
- 74 Cheenpracha S, Karalai C, Ponglimanont C, Subhadhirasakul S, Tewtrakul S. Anti-HIV-1 protease activity of compounds from Boesenbergia pandurata. Bioorg Med Chem. 2006; 14 1710-4
- 75 Mahmood N, Piacente S, Burke A, Khan A, Pizza C. Constituents of Cuscuta reflexa are anti-HIV agents. Antiviral Chem Chemother. 1997; 8 70-4
- 76 Yamaguchi K, Honda M, Ikigai H, Hara Y, Shimamura T. Inhibitory effects of (–)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res. 2002; 53 19-34
- 77 Williamson M P, McCormick T G, Nance C L, Shearer W T. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy. J Allergy Clin Immunol. 2006; 118 1369-74
- 78 Rowley D C, Hansen M ST, Rhodes D, Sotriffer C A, Ni H, McCammon J A. et al . Thalassiolins A-C: new marine-derived inhibitors of HIV cDNA integrase. Bioorg Med Chem. 2002; 10 3619-25
- 79 Groweiss A, Cardellina J H, Boyd M R. HIV-inhibitory prenylated xanthones and flavones from Maclura tinctoria. J Nat Prod. 2000; 63 1537-9
- 80 Cos P, De Bruyne T, Apers S, Vanden Berghe D, Pieters L, Vlietinck A J. Phytoestrogens: recent developments. Planta Med. 2003; 69 589-99
- 81 Wang Q, Ding Z H, Liu J K, Zheng Y T. Xanthohumol, a novel anti-HIV-1 agent purified from hops Humulus lupulus. Antiviral Res. 2004; 64 189-94
- 82 Lin Y M, Anderson H, Flavin M T, Pai Y HS, Mata-Greenwood E, Pengsuparp T. et al . In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod. 1997; 60 884-8
- 83 Reutrakul V, Ningnuek N, Pohmakotr M, Yoosook C, Napaswad C, Kasisit J. et al . Anti HIV-1 flavonoid glycosides from Ochna integerrima. Planta Med. 2007; 73 683-8
- 84 Alves C N, Pinheiro J C, Camargo A J, de Souza A J, Carvalho R B, da Silva A BF. A quantum chemical and statistical study of flavonoid compounds with anti-HIV activity. J Mol Struct (Theochem). 1999; 491 123-31
- 85 Mantas A, Deretey E, Ferretti F H, Estrada M R, Csizmadia I G. Structural analysis of flavonoids with anti-HIV activity. J Mol Struct (Theochem). 2000; 504 171-9
- 86 Alves C N, Pinheiro J C, Camargo A J, Ferreira M MC, Romero R AF, da Silva A BF. A multiple linear regression and partial least squares study of flavonoid compounds with anti-HIV activity. J Mol Struct (Theochem). 2001; 541 81-8
- 87 Tao J, Qinxue H, Yang J, Li R, Li X, Lu C. et al . In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate. Antiviral Res. 2007; 75 227-33
- 88 He Y, Zeng S. Transport characteristics of rutin deca (H-)sulfonate sodium across Caco-2 cell monolayers. J Pharm Pharmacol. 2005; 57 1297-303
- 89 Wang X J, Jin Y X, Ying J Y, Zeng S, Tao T W. Determination of rutin deca (H-)sulfate sodium in rat plasma using ion-pairing liquid chromatography after ion-pairing solid-phase extraction. J Chromatogr B. 2006; 833 231-5
- 90 Charlton J L. Antiviral activity of lignans. J Nat Prod. 1998; 61 1447-51
- 91 Valsaraj R, Pushpangadan P, Smitt U W, Adersen A, Christensen S B, Sittie A. et al . New anti-HIV-1, antimalarial, and antifungal compounds from Terminalia bellerica. J Med Chem. 1997; 60 739-42
- 92 Kuo Y H, Li S Y, Huang R L, Wu M D, Huang H C, Lee K H. Schizarin B, C, D and E, four new lignans from Kadsura matsudai and their antihepatitis activities. J Nat Prod. 2001; 64 487-90
- 93 Hoang V D, Tan G T, Zhang H J, Tamez P A, Van Hung N, Cuong N M. et al . Natural anti-HIV agents – part 1: (+)-demethoxyepiexcelsin and verticillatol from Litsea verticillata. Phytochemistry. 2002; 59 325-9
- 94 Sun Q Z, Chen D F, Ding P L, Ma C M, Kakuda H, Nakamura N. et al . Three new lignans, longipedunins A-C from Kadsura longipedunculata and their inhibitory activity against HIV-1 protease. Chem Pharm Bull. 2006; 54 129-32
- 95 Chen S W, Wang Y H, Jin Y, Tian X, Zheng Y T, Luo D Q. et al . Synthesis and anti-HIV-1 activities of novel podophyllotoxin derivatives. Bioorg Med Chem Lett. 2007; 17 2091-5
- 96 Zhu X K, Guan J, Xiao Z, Cosentino L M, Lee K H. Anti-AIDS agents. Part 61: anti-HIV activity of new podophyllotoxin derivatives. Bioorg Med Chem. 2004; 12 4267-73
- 97 Chen M, Kilgore N, Lee K H, Chen D F. Rubrisandrins A and B, lignans and related anti-HIV compounds from Schisandra rubriflora. J Nat Prod. 2006; 69 1697-701
- 98 Ovenden S PB, Wan S S, Sberna G, Tait R M, Rhodes D, Cox S. et al . Globoidnan A: a lignan from Eucalyptus globoidea inhibits HIV integrase. Phytochemistry. 2004; 65 3255-9
- 99 Piccinelli A L, Mahmood N, Mora G, Poveda L, De Simone F, Rastrelli L. Anti-HIV activity of dibenzylbutyrolactone-type lignans from Phenax species endemic in Costa Rica. J Pharm Pharmacol. 2005; 57 1109-15
- 100 McDougall B, King P J, Wu B W, Hostomsky Z, Reinecke M G, Robinson W E. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother. 1998; 42 140-6
- 101 Zhu K, Cordeiro M L, Atienza J, Robinson W E, Chow S A. Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. J Virol. 1999; 73 3309-16
- 102 King P J, Robinson W E. Resistance to the anti-human immunodeficiency virus type 1 compound l-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol. 1998; 72 8420-4
- 103 Pluymers W, Neamati N, Pannecouque C, Fikkert V, Marchand C, Burke T R. et al . Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol Pharmacol. 2000; 58 641-8
- 104 Sotriffer C A, Ni H, McCammon A. Active site binding modes of HIV-1 integrase inhibitors. J Med Chem. 2000; 43 4109-17
- 105 Lee D J, Robinson W E. Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors. Antimicrob Agents Chemother. 2006; 50 134-42
- 106 Lipinski C A, Lombardo F, Dominy B W, Feeney P J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 1997; 23 3-25
- 107 Veber D F, Johnson S R, Cheng H Y, Smith B R, Ward K W, Kopple K D. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45 2615-23
- 108 Kim S N, Lee J Y, Kim H J, Shin C G, Park H, Lee Y S. Synthesis and HIV-1 integrase inhibitory activities of caffeoylglucosides. Bioorg Med Chem Lett. 2000; 10 1879-82
- 109 Mazumder A, Neamati N, Sunder S, Schulz J, Pertz H, Eich E. et al . Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J Med Chem. 1997; 40 3057-63
- 110 Lin Z, Neamati N, Zhao H, Kiryu Y, Turpin J A, Aberham C. et al . Chicoric acid analogues as HIV-1 integrase inhibitors. J Med Chem. 1999; 42 1401-14
- 111 King P J, Ma G, Miao W, Jia Q, McDougall B R, Reinecke M G. et al . Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication. J Med Chem. 1999; 42 497-509
- 112 Artico M, Di Santo R, Costi R, Novellino E, Greco G, Massa S. et al . Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation and molecular modeling. J Med Chem. 1998; 41 3948-60
- 113 Charvat T T, Lee D J, Robinson W E, Chamberlin A R. Design, synthesis, and biological evaluation of chicoric acid analogs as inhibitors of HIV-1 integrase. Bioorg Med Chem. 2006; 14 4552-67
- 114 Mazumder A, Raghava K, Weinstein J, Kohn K W, Pommier Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem Pharmacol. 1995; 49 1165-70
- 115 Taher M M, Lammering G, Hershey C, Valerie K. Curcumin inhibits ultraviolet light induced human immunodeficiency virus gene expression. Mol Cell Biochem. 2003; 254 289-97
- 116 Balasubramnyam K, Varier R A, Altaf M, Swaminathan V, Siddappa N B, Ranga U. et al . Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem. 2004; 279 51 163-71
- 117 Appendino G, Ottino M, Marquez N, Bianchi F, Giana A, Ballero M. et al . Arzanol, and anti-inflammatory and anti-HIV-1 phloroglucinol α-pyrone from Helichrysum italicum spp. microphyllum. J Nat Prod. 2007; 70 608-12
- 118 Kim H J, Woo E R, Shin C G, Hwang D J, Park H, Lee Y S. HIV-1 integrase inhibitory phenylpropanoid glycosides from Clerodendron trichotomum. Arch Pharm Res. 2001; 24 286-91
- 119 Dat T N, Bae K, Wamiru A, McMahon J B, Le Grice S FJ, Bona M. et al . A dimeric lactone from Ardisia japonica with inhibitory activity for HIV-1 and HIV-2 Ribonuclease H. J Nat Prod. 2007; 70 839-41
- 120 O’Keefe B R. Biologically active proteins from natural product extracts. J Nat Prod. 2001; 64 1373-81
- 121 Peumans W J, Hao Q, Van Damme E JM. Ribosome-inactivating proteins from plants: more than RNA N-glycosidases?. Faseb J. 2001; 15 1493-06
- 122 Girbes T, Ferreras J M, Arias F J, Stirpe F. Description, distribution, activity and phylogenetic relationship of ribosome-inactivating proteins in plants, fungi and bacteria. Mini Rev Med Chem. 2004; 4 461-76
- 123 Szalai K, Schöll I, Förster-Waldl E, Polito L, Bolognesi A, Untersmayr E. et al . Occupational sensitization to ribosome-inactivating proteins in researchers. Clin Exp Allergy. 2005; 35 1354-60
- 124 Lee-Huang S, Huang P L, Bourinbaiar A S, Chen H C, Kung H F. Inhibition of the integrase of human immunodeficiency virus (HIV) type-1 by anti-HIV plant proteins MAP30 and GAP31. Proc Natl Acad Sci USA. 1995; 92 8818-22
- 125 Sun Y, Huang P L, Li J J, Huang Y Q, Zhang L, Huang P L. et al . Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi’s sarcoma-associated virus. Biochem Biophys Res Commun. 2001; 287 983-94
- 126 Wang Y X, Neamati N, Jacob J, Palmer I, Stahl S J, Kaufman J D. et al . Solution structure of anti-HIV-1 and anti-tumor protein MAP30: structural insights into its multiple functions. Cell. 1999; 99 433-42
- 127 Nicolas E, Beggs J M, Haltiwanger B M, Taraschi T F. A new class of DNA glycosylase apurinic/apyrimidinic lyases that act on specific adenines in single-stranded DNA. J Biol Chem. 1998; 273 17 216-20
- 128 Huang P L, Sun Y, Chen H C, Kung H F, Huang P L, Lee-Huang S. Proteolytic fragments of anti-HIV and anti-tumor proteins MAP30 and GAP31 are biologically active. Biochem Biophys Res Commun. 1999; 262 615-23
- 129 McGrath M S, Hwang K M, Caldwell S E, Gaston I, Luk K C, Wu P. et al . GLQ223 – an inhibitor of human immunodeficiency virus replication in acutely and chronically infected-cells of lymphocyte and mononuclear phagocyte lineage. Proc Natl Acad Sci USA. 1989; 86 2844-8
- 130 Byers V S, Levin A S, Malvino A, Waites L, Robins R A, Baldwin R W. A phase-II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents. AIDS Res Hum Retroviruses. 1994; 10 413-20
- 131 Chan S H, Shaw P C, Mulot S FC, Xu L H, Chan W L, Tam S C. et al . Engineering of a mini-trichosanthin that has lower antigenicity by deleting its C-terminal amino acid residues. Biochem Biophys Res Commun. 2000; 270 279-85
- 132 Wang Y Y, Ouyang D Y, Huang H, Chan H, Tam S C, Zheng Y T. Enhanced apoptotic action of trichosanthin in HIV-1 infected cells. Biochem Biophys Res Commun. 2005; 331 1075-80
- 133 Au T K, Collins R A, Lam T L, Ng T B, Fong W P, Wan D CC. The plant ribosome inactivating proteins luffin and saporin are potent inhibitors of HIV-1 integrase. FEBS Lett. 2000; 471 169-72
- 134 Balzarini J. Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res. 2006; 71 237-47
- 135 Balzarini J, Van Laethem K, Hatse S, Froeyen M, Peumans W, Van Damme E. et al . Carbohydrate-bindings agents cause deletions of highly conserved glycosylation sites in HIV gp120 – a new therapeutic concept to hit the Achilles heel of HIV. J Biol Chem. 2005; 280 41 005-14
- 136 Hu Q, Mahmood N, Shattock R J. High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanoverin-N and the impact on antibody neutralization. Virology. 2007; 368 145-54
- 137 Balzarini J. The α(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120. FEBS Lett. 2007; 581 2060-4
- 138 Balzarini J, Van Laethem K, Peumans W J, Van Damme E JM, Bolmstedt A, Gago F. et al . Mutational pathways, resistance profile, and side effects of cyanoverin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol. 2006; 80 8411-21
- 139 Botos I, Wlodawer A. Proteins that bind high-mannose sugars of the HIV envelope. Prog Biophys Mol Biol. 2005; 88 233-82
- 140 Saidi H, Nasreddine N, Jenabian M A, Lecerf M, Schols D, Krief D. et al . Differential in vitro inhibitory activity against HIV-1 of alpha-(1 – 3)- and alpha-(1 – 6)-d-mannose specific lectins: implication for microbicide development. J. Transl Med. 2007; 5 28-36
- 141 Balzarini J, Hatse S, Vermeire K, Princen K, Aquaro S, Perno C F. et al . Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother. 2004; 48 3858-70
- 142 Balzarini J, Van Laethem K, Hatse S, Vermeire K, De Clercq E, Peumans W. et al . Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J. Virol. 2004; 78 10 617-27
- 143 Balzarini J, Neyts J, Schols D, Hosoya M, Van Damme E, Peumans W. et al . The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Res. 1992; 18 191-207
- 144 An J, Liu J Z, Wu C F, Li J, Dai L, Van Damme E. et al . Anti-HIV I/II activity and molecular cloning of a novel mannose/sialic acid-binding lectin from rhizome of Polygonatum cyrtonema Hua. Acta Biochem Biophyi Sin. 2006; 38 70-8
- 145 Wang H X, Ng T B. Examination of lectins, polysaccharopeptide, polysaccharide, alkaloid, coumarin and trypsin inhibitors for inhibitory activity against human immunodeficiency virus reverse transcriptase and glycohydrolases. Planta Med. 2001; 67 669-72
- 146 Charan R D, Munro M HG, O’Keefe B R, Sowder R C, McKee T C, Currens M J. et al . Isolation and characterization of Myrianthus holstii lectin, a potent HIV-1 inhibitory protein from the plant Myrianthus holstii. J Nat Prod. 2000; 63 1170-4
- 147 Jiratchariyakul W, Wiwat C, Vongsakul M, Somanabandhu A, Leelamanit W, Fujii I. et al . HIV inhibitor from Thai bitter gourd. Planta Med. 2001; 67 350-3
- 148 Wang H, Ng T B. Ginkbilobin, a novel antifungal protein from Ginkgo biloba seeds with sequence similarity to embryo-abundant protein. Biochem Biophys Res Commun. 2000; 279 407-11
- 149 Boyd M R, Gustafson K R, McMahon J B, Shoemaker R H, O’Keefe B R, Mori T. et al . Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother. 1997; 41 1521-30
- 150 Asres K, Seyoum A, Veeresham C, Bucar F, Gibbons S. Naturally derived anti-HIV agents. Phytother Res. 2005; 19 557-81
- 151 Tsai C C, Emau P, Jiang Y, Tian B, Morton W R, Gustafson K R. et al . Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses. 2003; 19 535-41
- 152 Tsai C C, Emau P, Jiang Y, Agy M B, Shattock R J, Schmidt A. et al . Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses. 2004; 20 11-8
- 153 Giomarelli B, Provvedi R, Meacci F, Maggi T, Medaglini D, Pozzi G. et al . The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. AIDS. 2002; 16 1351-6
- 154 Lagenauer L A, Berger E A. An anti-HIV microbicide comes alive. Proc Natl Acad Sci USA. 2005; 102 12 294-5
- 155 Push O, Boden D, Hannify S, Lee F, Tucker L D, Boyd M R. et al . Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. J Acquir Immune Defic Syndr. 2005; 40 512-20
- 156 Bokesch H R, O’Keefe B R, McKee T C, Pannell L K, Patterson G M, Gardella R S. et al . A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry. 2003; 42 2578-84
- 157 Bewley C A, Cai M, Ray S, Ghirlando R, Yamaguchi M, Muramoto K. New carbohydrate specificity and HIV-1 fusion blocking activity of the cyanobacterial protein MVL: NMR, ITC and sedimentation equilibrium studies. J Mol Biol. 2004; 339 901-14
- 158 Mori T, O’Keefe B R, Sowder R C, Bringans S, Gardella R, Berg S. et al . Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem. 2005; 280 9345-53
- 159 Reutrakul V, Chanakul W, Pohmakotr M, Jaipetch T, Yoosook C, Kasisit J. et al . Anti-HIV-1 constituents from leaves and twigs of Cratoxylum arborescens. Planta Med. 2006; 72 1433-5
- 160 Dharmaratne H RW, Tan G T, Marasinghe G PK, Pezzuto J M. Inhibition of HIV-1 reverse transcriptase and HIV-1 replication by Calophyllum coumarins and xanthones. Planta Med. 2002; 68 86-7
- 161 Reutrakul V, Anantachoke N, Pohmakotr M, Jaipetch T, Sophasan S, Yoosook C. et al . Cytotoxic and anti-HIV-1 caged xanthones from the resin and fruits of Garcinia hanburyi. Planta Med. 2007; 73 33-40
- 162 De Bruyne T, Pieters L, Deelstra H, Vlietinck A. Condensed vegetable tannins: biodiversity in structure and biological activities. Biochem Syst Ecol. 1999; 27 445-9
- 163 Khanbabaee K, van Ree T. Tannins: classification and definition. Nat Prod Rep. 2001; 18 641-9
- 164 Amouroux P, Jean D, Lamaison J L. Antiviral activity in vitro of Cupressus sempervirens on two human retroviruses HIV and HTLV. Phytother Res. 1998; 12 367-8
- 165 Ma C M, Nakamura N, Hattori M, Kakuda H, Qiao J C, Yu H L. Inhibitory effects on HIV-1 protease of constituents from the wood of Xanthoceras sorbifolia. J Nat Prod. 2000; 63 238-42
- 166 De Bruyne T, Pieters L, Witvrouw M, De Clercq E, Vanden Berghe D, Vlietinck A J. Biological evaluation of proanthocyanidin dimers and related polyphenols. J Nat Prod;. 1999; 62 954-8
- 167 Liu S, Lu H, Zhao Q, He Y, Niu J, Debnath A K. et al . Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta. 2005; 1723 270-81
- 168 Notka F, Meier G, Wagner R. Concerted inhibitory activities of Phyllanthus amarus on HIV replication in vitro and ex vivo. Antiviral Res. 2004; 64 93-102
- 169 Zhang H J, Huang N V, Cuong N M, Soejarto D D, Pezzuto J M, Fong H HS. et al . Sesquiterpenes and butenolides, natural anti-HIV constituents from Litsea verticillata. Planta Med. 2005; 71 452-7
- 170 Min B S, Hattori M, Lee K H, Kim Y H. Inhibitory constituents against HIV-1 protease from Agastache rugosa. Arch Pharm Res. 1999; 22 75-7
- 171 Rashid M A, Gustafson K R, Boyd M R. HIV-inhibitory cembrane derivatives from a Philippines collection of the soft coral Lobophytum species. J Nat Prod. 2000; 63 531-3
- 172 Alam M S, Quader M A, Rashid A A. HIV-inhibitory diterpenoid from Anisomeles indica. . Fitoterapia. 2000; 71 574-6
- 173 Barbosa J P, Pereira R C, Abrantes J L, Dos Santos C CC, Rebello M A, Frugulhetti I CPP. et al . In vitro antiviral diterpenes from the Brazil brown alga Dictyota pfaffii. Planta Med. 2004; 70 856-60
- 174 Cirne-Santos C C, Teixeira V L, Castello-Branco L R, Frugulheti I CPP, Bou-Habid D C. Inhibition of HIV-1 replication in human primary cells by a dolabellane diterpene isolated from the marine algae Dictyota pfaffii. Planta Med. 2006; 72 295-9
- 175 Pereira H S, Leao-Ferreira L R, Moussatché N, Teieira V L, Cavalcanti D N, da Costa L J. et al . Effects of diterpenes isolated from the Brazilian marine alga Dictyota menstrualis on HIV-1 reverse transcriptase. Planta Med. 2005; 71 1019-24
- 176 Rukachaisirikul V, Pailee P, Hiranrat A, Tuchinda P, Yoosook C, Kasisit C. et al . Anti-HIV-1 prostane triterpenes and digeranylbenzophenone from trunk bark and stems of Garcinia speciosa. Planta Med. 2003; 69 1141-6
- 177 Battinelli L, Mengoni F, Lichtner M, Mazzanti G, Saija A, Mastroianni C M. et al . Effect of limonin and nomilin on HIV-1 replication on infected human mononuclear cells. Planta Med. 2003; 69 910-3
- 178 Chen D F, Zhang S X, Wang H K, Zhang S Y, Sun Q Z, Cosentino L M. et al . Novel anti-HIV lancilactone C and related triterpenes from Kadsura lancilimba. J Nat Prod. 1999; 62 94-7
- 179 Xiao W L, Tian R R, Pu J X, Li X, Wu L, Lu Y. et al . Triterpenoids from Schisandra lancifolia with anti-HIV-1 activity. J Nat Prod. 2006; 69 277-9
- 180 Huang L, Chen C H. Molecular targets of anti-HIV-1 triterpenes. Curr Drug Target Infect Disord. 2002; 2 33-6
- 181 Mengoni F, Lichtner M, Battinelli L, Marzi M, Mastroianni C M, Vullo V. et al . In vitro anti-HIV activity of oleanolic acid on infected human mononuclear cells. Planta Med. 2002; 68 111-4
- 182 Sun I C, Shen J K, Wang H K, Cosentino L M, Lee K H. Anti-AIDS agents. 32. Synthesis and anti-HIV activity of betulin derivatives. Bioorg Med Chem Lett. 1998; 8 1267-72
- 183 Kashiwada Y, Wang H K, Nagao T, Kitanaka S, Yasuda I, Fujioka T. Anti-AIDS agents. 30. Anti-HIV activity of oleanolic acid, pomolic acid, and structurally related triterpenoids. J Nat Prod. 1998; 61 1090-5
- 184 Kashiwada Y, Nagao T, Hashimoto A, Ikeshiro Y, Okabe H, Cosentino L M. et al . Anti-AIDS agents 38. Anti-HIV activity of 2-O-acylursolic acid derivatives. J Nat Prod. 2000; 63 1619-22
- 185 Zhou J, Yuan X, Dismuke D, Forshey B M, Lundquist C, Lee K H. et al . Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol. 2004; 78 922-9
- 186 Lee K H. Current developments in the discovery and design of new drug candidates from plant natural product leads. J Nat Prod. 2004; 67 273-83
- 187 Kashiwada Y, Chiyo J, Ikeshiro Y, Nagao T, Okabe H, Cosentino L M. et al . 3,28-Di-O-(dimethylsuccinyl)-betulin isomers as anti-HIV agents. Bioorg Med Chem Lett. 2001; 11 183-5
- 188 Sami A, Taru M, Salme K, Jari Y K. Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci. 2006; 29 1-13
- 189 Soler F, Poujade C, Evers M, Carry J C, Hénin Y, Bousseau A. et al . Betulinic acid derivatives: A new class of specific inhibitors of human immunodeficiency virus type 1 entry. J Med Chem. 1996; 39 1069-83
- 190 Evers M, Poujade C, Soler F, Ribeill Y, James C, Lelièvre Y. et al . Betulinic acid derivatives: A new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action. J Med Chem. 1996; 39 1056-68
- 191 Labrosse B, Treboute C, Alizon M. Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region. J Virol. 2000; 74 2142-50
- 192 Holz-Smith S L, Sun I C, Jin L, Matthews T J, Lee K H, Chen C H. Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564. Antimicrob Agents Chemother. 2001; 45 60-6
- 193 Huang L, Zhang L, Chen C H. Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41. Curr Pharm Design. 2003; 9 1453-62
- 194 Huang L, Yuan X, Aiken C, Chen C H. Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action. Antimicrob Agents Chemother. 2004; 48 663-5
- 195 Aiken C, Chen C H. Betulinic acid derivatives as HIV-1 antivirals. Trends Molecular Med. 2005; 11 31-6
Prof. Dr. Paul Cos
Laboratory of Microbiology, Parasitology and Hygiene (LMPH)
Department of Pharmaceutical Sciences
University of Antwerp
Groenenborgerlaan 171
2020 Antwerp
Belgium
Phone: +32-3-265-3217
Email: paul.cos@ua.ac.be